For two decades, many women heard that hormone therapy was risky and many clinicians hesitated to prescribe it. In February 2026, the FDA approved label changes that removed boxed warnings about cardiovascular disease, breast cancer, and probable dementia from the first six menopausal hormone therapy products. The shift has renewed interest in a treatment that remains effective for selected symptoms.
“Comeback” here describes a more individualized conversation, not a universal recommendation. Menopause hormone therapy is an established treatment for certain symptoms, and it is not right for everyone. Systemic therapy, taken to affect the whole body, differs from low-dose vaginal estrogen, which treats local symptoms. This article explains the evidence, treatment types, risks, and questions worth raising with a qualified clinician.
Why Hormone Therapy Is Back in the Conversation
In 2002, the Women’s Health Initiative (WHI) stopped its estrogen plus progestin trial early. The combination group showed higher rates of breast cancer, coronary events, stroke, and blood clots, along with fewer hip fractures and colorectal cancers. Prescribing fell sharply.
Later analyses added nuance. Participants averaged about 63 years old, and many were more than a decade past menopause. Risks differ by age, timing, formulation, route, and baseline health. Long-term WHI follow-up found estrogen alone was associated with lower breast cancer incidence, while the combination was associated with higher incidence.
The FDA announced its plan in November 2025 and approved the first batch of label changes on February 12, 2026. The agency retained a boxed warning for endometrial cancer on systemic estrogen-alone products for women with a uterus, because adding a progestogen mitigates that risk. Experts also expect updated guidance that favors starting therapy before age 60 or within 10 years of menopause onset.
None of this means earlier concerns have vanished or that hormone therapy prevents aging. Risks remain real for some people. The change reflects a more precise reading of the evidence.
What Happens to Hormones During Menopause
Ovarian estrogen production declines and progesterone changes. Three stages help organize the transition:
- Perimenopause: Hormones fluctuate, periods become irregular, and symptoms often begin.
- Menopause: Twelve months without a period, at a median age near 51 in the United States.
- Postmenopause: The years afterward, when estrogen stays low.
Low estrogen is linked to vasomotor symptoms such as hot flashes and night sweats, genitourinary symptoms, sleep disruption, and bone loss. Some symptoms overlap with other conditions, including thyroid disease, anemia, and depression. Heavy or unexpected bleeding, severe symptoms, or symptoms outside the usual age range warrant evaluation.
Which Symptoms Can Hormone Therapy Treat?
Hot flashes and night sweats
Vasomotor symptoms affect most women, and in the SWAN study they lasted a median of about seven years. They can interrupt sleep and daily life. Systemic hormone therapy is the most effective established treatment for appropriate candidates.
Vaginal dryness and genitourinary symptoms
Genitourinary syndrome of menopause includes dryness, pain with sex, and urinary symptoms. Low-dose vaginal estrogen treats these locally with generally lower systemic exposure. Nonhormonal moisturizers and other options also exist.
Sleep and quality of life
When night sweats drive poor sleep, treating them may help sleep indirectly. Hormone therapy is not a treatment for every form of insomnia.
Bone health
Estrogen deficiency speeds bone loss. Hormone therapy can prevent bone loss in selected patients, but osteoporosis treatment involves broader assessment and other medications.
Types of Menopause Hormone Therapy
| Treatment type | Common use | Important consideration |
|---|---|---|
| Estrogen only | Systemic therapy, mainly for women without a uterus | Suitability depends on medical history |
| Estrogen plus progestogen | Systemic therapy for women with a uterus | Progestogen protects the uterine lining |
| Low-dose vaginal estrogen | Local genitourinary symptoms | Generally lower systemic exposure |
| Transdermal estrogen | Patch, gel, or spray | Different clot risk profile than oral |
| Oral estrogen | Systemic therapy | Requires individual risk review |
| Nonhormonal therapies | Selected symptoms | Benefits vary by option |
The right choice depends on symptoms, uterine status, health history, and preference. Compounded “bioidentical” hormones are not automatically safer or more effective than approved products. They are not FDA-approved, and ACOG advises against routine use.
How Doctors Assess Whether It Is Appropriate
Clinicians weigh symptom severity, age, time since menopause, personal and family history, and the patient’s priorities. Conditions that raise caution or rule out therapy include unexplained vaginal bleeding, previous hormone-sensitive cancers, a history of blood clots or stroke, active liver disease, and some cardiovascular conditions.
Routine hormone testing is generally unnecessary to diagnose menopause in typical cases at the usual age, though clinical circumstances vary. The process is shared decision making: symptoms are assessed, history reviewed, options discussed, a plan started, and follow-up scheduled.
Benefits and Risks in Balance
| Consideration | What the evidence addresses |
|---|---|
| Vasomotor symptoms | Strong symptom relief and quality of life gains |
| Bone health | Prevention of bone loss and fracture reduction |
| Breast cancer | Differences by formulation, duration, and population |
| Blood clots | Higher with oral than transdermal in many studies |
| Stroke and cardiovascular outcomes | Depends on age, timing, baseline risk, formulation |
| Endometrial health | Progestogen needed with a uterus |
| Vaginal symptoms | Local treatment is effective |
| Long-term use | Periodic reassessment and individual decisions |
Absolute and relative risk differ. In the WHI combination trial, the excess was on the order of 8 additional invasive breast cancers per 10,000 women per year. A percentage increase can sound large while the absolute number remains small, and risks seen in one population may not apply equally to another. Neither “dangerous” nor “risk-free” is accurate.
Absolute Risk in Plain Terms
Relative risk describes how much a risk changes. Absolute risk describes how many people are affected. If a baseline risk is 3 cases per 1,000 women a year and a treatment raises it by 25 percent, the new risk is about 3.75 per 1,000. The relative number sounds large, while the absolute increase is under one extra case per 1,000 women.
Baseline risk matters too. A woman with a strong family history of breast cancer or existing heart disease starts from a different baseline than a healthy woman at 52, so the same percentage change means something different. This is why clinicians ask about personal history before discussing numbers.
What a Consultation May Look Like
A visit typically starts with symptoms: how often hot flashes occur, whether sleep is disrupted, and how much they affect work and relationships. The clinician reviews medical, surgical, and family history, checks blood pressure, and may order screening that is already due, such as a mammogram.
The conversation then turns to options, including hormone and nonhormonal choices, expected benefits, and side effects such as breast tenderness or spotting. A follow-up date is set to see whether symptoms improved. This is a general illustration of shared decision making, not a treatment plan for any individual.
The Women’s Health Initiative in Numbers
| Detail | Estrogen plus progestin trial | Estrogen-alone trial |
|---|---|---|
| Participants | About 16,600 women with a uterus | About 10,700 women without a uterus |
| Average age at enrollment | About 63 | About 63 |
| Stopped early | 2002, after about 5.2 years | 2004, after about 7.2 years |
| Notable findings | Higher breast cancer, stroke, clots, coronary events; fewer fractures and colorectal cancers | Higher stroke and clots; lower breast cancer in later follow-up |
Two features of the trials shaped later debate. First, participants were older than the typical woman who seeks treatment for hot flashes, so results may not transfer to women in their early 50s. Second, the trials used one oral estrogen and one progestin, so conclusions do not automatically apply to other formulations or routes.
Later studies tested the timing idea directly. The ELITE trial found that oral estradiol slowed progression of carotid artery thickening in women within six years of menopause but not in those more than ten years past it. That finding supports the view that timing influences cardiovascular effects, though it measured an imaging marker, not heart attacks.
Why Timing and Route Matter
Starting near menopause, in women under 60, generally has a more favorable balance than starting many years later. Oral and transdermal estrogen differ in how the body processes them. Oral estrogen passes through the liver and affects clotting factors, while transdermal delivery bypasses that first pass. Observational data suggest lower clot risk with transdermal use, but no route fits everyone.
What Newer Menopause Care Looks Like
Menopause is getting more attention in primary care and specialist clinics. Personalized plans, symptom monitoring, and patient education are expanding, with gynecologists, primary care clinicians, and menopause specialists all involved. Barriers remain, including misinformation, limited specialist access, and gaps in clinician training.
Nonhormonal Alternatives
- Prescription options: Fezolinetant, a neurokinin 3 receptor antagonist, treats hot flashes, but liver injury warnings require monitoring. A second drug in this class, elinzanetant, has also been approved. Low-dose paroxetine, venlafaxine, and gabapentin are other options.
- Cognitive behavioral therapy: It can help with hot flash distress and sleep problems.
- Lifestyle: Physical activity, regular sleep routines, and quitting smoking support general health but do not replace effective symptom treatment.
- Supplements and herbs: Evidence is limited and quality varies, so caution is warranted.
Questions to Ask Before Starting or Continuing
- Which symptoms is treatment meant to address?
- Which formulations are available?
- Do my personal risk factors change the options?
- Is systemic or local treatment more appropriate?
- What benefits should I expect, and when?
- Which side effects need medical review?
- When will treatment be reassessed?
- What alternatives exist?
- What happens if symptoms persist?
What Each Question in the Consultation Checklist Means
The checklist helps patients prepare. Each question has a purpose.
Which symptoms is treatment meant to address? Therapy is chosen for specific problems, such as hot flashes or vaginal dryness. Naming the target helps judge later whether it worked.
Which formulations are available? Options include pills, patches, gels, sprays, vaginal rings, tablets, and creams, with different doses and risk profiles.
Do my personal risk factors change the options? Family history of breast cancer, past blood clots, migraine with aura, smoking, and blood pressure all influence the choice.
Is systemic or local treatment more appropriate? If only vaginal symptoms bother a patient, low-dose local estrogen may be enough and avoids exposing the whole body to higher doses.
What benefits should I expect, and when? Hot flash relief often begins within weeks, and a clear expectation prevents disappointment or unnecessary dose increases.
Which side effects need medical review? Unexpected vaginal bleeding, breast lumps, severe headaches, leg swelling, chest pain, and vision changes should prompt contact with a clinician.
When will treatment be reassessed? Periodic review, often yearly, checks whether symptoms persist and whether the balance of benefit and risk has changed.
What alternatives exist? Knowing nonhormonal options allows a real choice.
What if symptoms persist? A plan for next steps, such as dose change, a different route, or referral, avoids trial and error without direction.
Comparing Nonhormonal Options
| Option | Type | Key considerations |
|---|---|---|
| Fezolinetant | Neurokinin 3 receptor antagonist, FDA approved 2023 | Liver injury warning; liver monitoring needed |
| Elinzanetant | Neurokinin receptor antagonist, approved later | Newer; discuss side effects such as sleepiness |
| Low-dose paroxetine | SSRI approved for hot flashes | Interacts with tamoxifen; avoid in some patients |
| Venlafaxine | SNRI, off-label for hot flashes | May raise blood pressure; useful when mood symptoms exist |
| Gabapentin | Anticonvulsant, off-label | Can help night sweats; may cause drowsiness |
| Cognitive behavioral therapy | Behavioral | Reduces distress and improves sleep; does not eliminate hot flashes |
Hormone therapy remains the most effective treatment for hot flashes, but nonhormonal choices are important for people who cannot or prefer not to take hormones, including many breast cancer survivors.
The Future of Menopause Care
Expect more personalized approaches, better clinician education, improved symptom recognition, and ongoing research on safety. Further recommendations will depend on clinical evidence, regulatory decisions, and updated professional guidelines. Emerging therapies are not established standards until the evidence says so.
Informed Choice, Reassessed Over Time
Hormone therapy can bring meaningful relief to selected patients, and the balance of benefit and risk differs for each person. Good menopause care means informed decisions, suitable treatment, and periodic review, not one approach for all. A personal conversation with a qualified clinician is the right next step.
The renewed conversation around hormone therapy also reflects a wider shift in how medicine treats midlife health. Menopause was long treated as a private matter or a normal transition requiring no care. Research now links symptoms to sleep loss, work productivity, relationships, and long-term bone and cardiovascular health, and clinicians are being trained to ask about it.
For patients, the practical message is that a good conversation can begin with a short list. It might include the three most bothersome symptoms, current medications, personal and family history, and preferences about treatment. With that information, a clinician can discuss options in a way that fits the person, not an average.
Disclaimer: This article is for general educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Menopause treatment decisions should be made with a qualified healthcare professional after considering individual symptoms, medical history, benefits, risks, and preferences.
FAQ
Q: Why is menopause hormone therapy receiving renewed attention?
A: Reanalysis of older trials and FDA label changes in 2026 have encouraged more individualized, age-and-timing-based decisions.
Q: What are the main benefits of hormone replacement therapy?
A: It relieves hot flashes and night sweats, treats vaginal symptoms, and helps prevent bone loss in selected patients.
Q: Is hormone therapy safe for women over 50?
A: Safety depends on age, time since menopause, health history, and formulation. Many healthy women under 60 or near menopause have a favorable balance, but a clinician should decide.
Q: What is the difference between estrogen-only and combined hormone therapy?
A: Estrogen-only is generally used when the uterus has been removed. Combined therapy adds a progestogen to protect the uterine lining.
Q: Is vaginal estrogen different from systemic hormone therapy?
A: Yes. Low-dose vaginal estrogen treats local symptoms with generally lower systemic exposure than pills, patches, or gels.
Q: Does hormone therapy increase breast cancer risk?
A: Risk varies. The WHI found higher incidence with estrogen plus progestin and lower incidence with estrogen alone, and absolute increases are small.
Q: Can hormone therapy improve sleep during menopause?
A: It can help when night sweats disrupt sleep, but it does not treat all insomnia.
Q: How long can someone take menopause hormone therapy?
A: Duration is individualized, with periodic reassessment of symptoms, benefits, and risks.
Q: What are the alternatives to hormone therapy?
A: Nonhormonal prescription medicines, cognitive behavioral therapy, vaginal moisturizers, and lifestyle measures.
Q: Do all women need hormone therapy during menopause?
A: No. Many women have mild symptoms or prefer other approaches.